Smith & Nephew SNATS, Inc. $SNN Holdings Trimmed by Quadrant Capital Group LLC

Quadrant Capital Group LLC trimmed its position in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) by 67.3% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 13,457 shares of the medical equipment provider’s stock after selling 27,717 shares during the period. Quadrant Capital Group LLC’s holdings in Smith & Nephew SNATS were worth $375,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in SNN. Parallel Advisors LLC lifted its holdings in shares of Smith & Nephew SNATS by 20.0% in the first quarter. Parallel Advisors LLC now owns 2,322 shares of the medical equipment provider’s stock valued at $74,000 after purchasing an additional 387 shares in the last quarter. Clearstead Trust LLC acquired a new stake in shares of Smith & Nephew SNATS in the second quarter worth $25,000. Ritholtz Wealth Management grew its holdings in shares of Smith & Nephew SNATS by 6.0% during the first quarter. Ritholtz Wealth Management now owns 11,157 shares of the medical equipment provider’s stock valued at $355,000 after buying an additional 633 shares in the last quarter. Versant Capital Management Inc grew its holdings in shares of Smith & Nephew SNATS by 7.9% during the third quarter. Versant Capital Management Inc now owns 8,852 shares of the medical equipment provider’s stock valued at $239,000 after buying an additional 647 shares in the last quarter. Finally, Addison Advisors LLC purchased a new position in shares of Smith & Nephew SNATS during the second quarter valued at $43,000. 25.64% of the stock is owned by institutional investors and hedge funds.

Smith & Nephew SNATS Trading Down 1.1%

Shares of NYSE:SNN opened at $30.48 on Tuesday. The firm has a fifty day moving average of $28.26 and a two-hundred day moving average of $31.17. Smith & Nephew SNATS, Inc. has a 12-month low of $26.12 and a 12-month high of $37.09. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.14 and a quick ratio of 1.11.

Smith & Nephew SNATS Announces Dividend

The firm also recently disclosed a dividend, which will be paid on Friday, November 6th. Investors of record on Friday, October 2nd will be paid a $0.3120 dividend. This represents a dividend yield of 236.0%. The ex-dividend date of this dividend is Friday, October 2nd.

Analysts Set New Price Targets

SNN has been the topic of several recent analyst reports. Bank of America lowered Smith & Nephew SNATS from a “buy” rating to a “neutral” rating in a research report on Tuesday, September 8th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Smith & Nephew SNATS in a research report on Thursday, August 6th. BTIG Research began coverage on Smith & Nephew SNATS in a research note on Monday, August 31st. They set a “neutral” rating on the stock. Zacks Research raised Smith & Nephew SNATS from a “strong sell” rating to a “hold” rating in a research note on Tuesday, September 8th. Finally, Berenberg Bank set a $33.88 target price on Smith & Nephew SNATS in a report on Friday, September 11th. One research analyst has rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Smith & Nephew SNATS currently has a consensus rating of “Hold” and an average price target of $31.91.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company that develops and manufactures products used by healthcare professionals to treat injuries, manage wounds and restore patients’ mobility. Founded in 1856 by Thomas James Smith in Hull, England, the company has grown from a pharmacy business into an international healthcare manufacturer.

The company operates across three principal areas: orthopaedics, sports medicine and ear, nose and throat (ENT), and advanced wound management.